2013 SCK•CEN annual report: interview with E. D'Agostino

on . Posted in Press releases

With 12.6 million new cases and 7.5 million deaths each year, cancer remains a major public health issue. Some 50 to 60% of patients undergo radiotherapy, sometimes in combination with surgery or drugs, as part of their treatment. DoseVue NV, the first spin-off at SCK •CEN, is developing technology to make high-dose radiotherapy more accurate and efficacious. Emiliano D’Agostino is one of the two founding partners of DoseVue, a promising new firm based in Hasselt (continue on page 85)

Interreg cross border innovation

on . Posted in Press releases

The new GCS innovation fund targets at financing cross-border innovation projects between technology-oriented small and medium-sized enterprises (SME) in the Greater Euregio Meuse-Rhine area. It is furnished with an overall volume of 4.7 million €, providing subsidies for each innovation project between € 100,000 and 250,000. The funding is provided on the basis of a competition as non-repayable grants on condition that the partners involved put up at least the same amount as equity capital. The fund is aimed at SMEs in the fields of health/life sciences, high-tech systems (including sectors such as energy, information and communication technology, automotive, mechanical engineering) as well as advanced materials/chemistry.

2013 Innotek annual report: interview with E. D'Agostino

on . Posted in Press releases

DoseVue is de eerste spin-off van het Studiecentrum voor Kernenergie (SCK) in Mol die dosimetrie bij patiënten bepaalt. Dosimetrie heeft als doel om bestralingen mogelijk te maken met de juiste dosis en op de exacte plaats. Uniek aan dit onderzoek is dat het rechtstreeks bij patiënten wordt uitgevoerd: in de tumor en op een niet-invasieve manier (continue on page 16).